Abstract
Value of chemoradiotherapy in bladder cancer: Standard treatment for muscle-invasive bladder cancer is cystectomy. Trimodality treatment, including transurethral resection of the bladder tumor (TUR), radiation therapy and chemotherapy, has been shown to produce survival rates comparable to those of primary cystectomy. With these programs, salvage cystectomy has been reserved for patients with incomplete response or local relapse. During the past decades, organ preservation by trimodality treatment has been investigated in prospective series from single centers and cooperative groups, with more than 1,000 patients included. Five-year overall survival rates in the range of 50 to 70 % and higher have been reported, and approximately three-quarters of the surviving patients maintained their own functioning bladder. Clinical criteria helpful in determining ideal patients for bladder preservation include early tumor stage (including high-risk T1 disease), a visibly complete TUR, and absence of ureteral obstruction. Close coordination among all disciplines is required to achieve optimal results. Future investigations will focus on optimizing radiation techniques and incorporating more effective systemic chemotherapy and targeted agents, and the proper selection of patients based on molecular makers.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Rodel C, Weiss C, Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol. 2006;24:5536–44.
Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374:239–49.
Rodel C. Current status of radiation therapy and combined-modality treatment for bladder cancer. Strahlenther Onkol. 2004;180:701–9.
Shipley WU, Prout Jr GR, Einstein AB, et al. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA. 1987;258:931–5.
Housset M, Maulard C, Chretien Y, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol. 1993;11:2150–7.
Sauer R, Dunst J, Altendorf-Hofmann A, et al. Radiotherapy with and without cisplatin in bladder cancer. Int J Radiat Oncol Biol Phys. 1990;19:687–91.
Kachnic LA, Kaufman DS, Heney NM, et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol. 1997;15:1022–9.
Tester W, Porter A, Asbell S, et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys. 1993;25:783–90.
Tester W, Caplan R, Heaney J, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol. 1996;14:119–26.
Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol. 1998;16:3576–83.
Zietman AL, Shipley WU, Kaufman DS, et al. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer. J Urol. 1998;160:1673–7.
Kaufman DS, Winter KA, Shipley WU, et al. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist. 2000;5:471–6.
Hagan MP, Winter KA, Kaufman DS, et al. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys. 2003;57:665–72.
Russell KJ, Boileau MA, Higano C, et al. Combined 5-fluorouracil and irradiation for transitional cell carcinoma of the urinary bladder. Int J Radiat Oncol Biol Phys. 1990;19:693–9.
Rotman M, Aziz H, Porrazzo M, et al. Treatment of advanced transitional cell carcinoma of the bladder with irradiation and concomitant 5-fluorouracil infusion. Int J Radiat Oncol Biol Phys. 1990;18:1131–7.
Given RW, Parsons JT, McCarley D, et al. Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: a five-year follow-up. Urology. 1995;46:499–504.
Housset M, Dufour B, Maulard-Durdux C, Chretien Y, Mejean A. Concomitant fluorouracil (5-FU)-cisplatin (CDDP) and bifractionated split course radiation therapy (BSCRT) for invasive bladder cancer. Proc Am Soc Clin Oncol. 1997;16:319a. Abstract.
Varveris H, Delakas D, Anezinis P, et al. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control. Anticancer Res. 1997;17:4771–80.
Fellin G, Graffer U, Bolner A, et al. Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-institution phase II study. Br J Urol. 1997;80:44–9.
Cervek J, Cufer T, Zakotnik B, et al. Invasive bladder cancer: our experience with bladder sparing approach. Int J Radiat Oncol Biol Phys. 1998;41:273–8.
Zapatero A, Martin de Vidales C, Marin A, et al. Invasive bladder cancer: a single-institution experience with bladder-sparing approach. Int J Cancer. 2000;90:287–94.
Arias F, Dominguez MA, Martinez E, et al. Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program. Int J Radiat Oncol Biol Phys. 2000;47:373–8.
Rodel C, Grabenbauer GG, Kuhn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002;20:3061–71.
Chen WC, Liaw CC, Chuang CK, et al. Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2003;56:726–33.
Peyromaure M, Slama J, Beuzeboc P, et al. Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution. Urology. 2004;63:73–7.
Danesi DT, Arcangeli G, Cruciani E, et al. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results. Cancer. 2004;101:2540–8.
Hussain SA, Stocken DD, Peake DR, et al. Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. Br J Cancer. 2004;90:2106–11.
Kragelj B, Zaletel-Kragelj L, Sedmak B, et al. Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer. Radiother Oncol. 2005;75:44–7.
Dunst J, Diestelhorst A, Kuhn R, et al. Organ-sparing treatment in muscle-invasive bladder cancer. Strahlenther Onkol. 2005;181:632–7.
Shipley WU, Kaufman DS, Zehr E, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology. 2002;60:62–7. discussion 67-68.
Efstathiou JA, Spiegel DY, Shipley WU, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2012;61:705–11.
Krause FS, Walter B, Ott OJ, et al. 15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment. Anticancer Res. 2011;31:985–90.
Kaufman DS, Winter KA, Shipley WU, et al. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology. 2009;73:833–7.
Mitin T, Hunt D, Shipley WU, et al. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol. 2013;14(9):863–72.
Muller AC, Diestelhorst A, Kuhnt T, et al. Organ-sparing treatment of advanced bladder cancer: paclitaxel as a radiosensitizer. Strahlenther Onkol. 2007;183:177–83.
Wittlinger M, Rodel CM, Weiss C, et al. Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia. Radiother Oncol. 2009;93(2):358–63.
Caffo O, Fellin G, Graffer U, et al. Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer: long-term cumulative results of 2 prospective single-institution studies. Cancer. 2011;117:1190–6.
Caffo O, Fellin G, Graffer U, et al. Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer. Int J Radiat Oncol Biol Phys. 2003;57:1310–6.
Kent E, Sandler H, Montie J, et al. Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial. J Clin Oncol. 2004;22:2540–5.
Oh KS, Soto DE, Smith DC, et al. Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial. Int J Radiat Oncol Biol Phys. 2009;74:511–7.
Sangar VK, McBain CA, Lyons J, et al. Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer. Int J Radiat Oncol Biol Phys. 2005;61:420–5.
Choudhury A, Swindell R, Logue JP, et al. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J Clin Oncol. 2011;29:733–8.
Zapatero A, Martin De Vidales C, Arellano R, et al. Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy. Urology. 2012;80:1056–62.
James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366:1477–88.
Tunio MA, Hashmi A, Qayyum A, et al. Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience. Int J Radiat Oncol Biol Phys. 2012;82:e457–62.
Greven KM, Solin LJ, Hanks GE. Prognostic factors in patients with bladder carcinoma treated with definitive irradiation. Cancer. 1990;65:908–12.
Smaaland R, Akslen LA, Tonder B, et al. Radical radiation treatment of invasive and locally advanced bladder carcinoma in elderly patients. Br J Urol. 1991;67:61–9.
Moonen L, vd Voet H, de Nijs R, et al. Muscle-invasive bladder cancer treated with external beam radiation: influence of total dose, overall treatment time, and treatment interruption on local control. Int J Radiat Oncol Biol Phys. 1998;42:525–30.
Quilty PM, Kerr GR, Duncan W. Prognostic indices for bladder cancer: an analysis of patients with transitional cell carcinoma of the bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol. 1986;7:311–21.
Pollack A, Zagars GK, Swanson DA. Muscle-invasive bladder cancer treated with external beam radiotherapy: prognostic factors. Int J Radiat Oncol Biol Phys. 1994;30:267–77.
Shipley WU, Rose MA, Perrone TL, et al. Full-dose irradiation for patients with invasive bladder carcinoma: clinical and histological factors prognostic of improved survival. J Urol. 1985;134:679–83.
Pos FJ, Hart G, Schneider C, et al. Radical radiotherapy for invasive bladder cancer: what dose and fractionation schedule to choose? Int J Radiat Oncol Biol Phys. 2006;64:1168–73.
Naslund I, Nilsson B, Littbrand B. Hyperfractionated radiotherapy of bladder cancer. A ten-year follow-up of a randomized clinical trial. Acta Oncol. 1994;33:397–402.
Goldobenko GV, Matveev BP, Shipilov VI, et al. Radiation treatment of bladder cancer using different fractionation regimens. Med Radiol (Mosk). 1991;36:14–6.
Stuschke M, Thames HD. Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials. Int J Radiat Oncol Biol Phys. 1997;37:259–67.
Maciejewski B, Majewski S. Dose fractionation and tumour repopulation in radiotherapy for bladder cancer. Radiother Oncol. 1991;21:163–70.
Horwich A, Dearnaley D, Huddart R, et al. A randomised trial of accelerated radiotherapy for localised invasive bladder cancer. Radiother Oncol. 2005;75:34–43.
Kob D, Arndt J, Kriester A, et al. Results of percutaneous radiotherapy of bladder cancer using 1 and 2 series of irradiation. Strahlenther Onkol. 1985;161:673–7.
Foroudi F, Wong J, Kron T, et al. Online adaptive radiotherapy for muscle-invasive bladder cancer: results of a pilot study. Int J Radiat Oncol Biol Phys. 2011;81:765–71.
McDonald F, Lalondrelle S, Taylor H, et al. Clinical implementation of adaptive hypofractionated bladder radiotherapy for improvement in normal tissue irradiation. Clin Oncol (R Coll Radiol). 2013;25(9):549–56.
Pos FJ, Hulshof M, Lebesque J, et al. Adaptive radiotherapy for invasive bladder cancer: a feasibility study. Int J Radiat Oncol Biol Phys. 2006;64:862–8.
Sondergaard J, Olsen KO, Muren LP, et al. A study of image-guided radiotherapy of bladder cancer based on lipiodol injection in the bladder wall. Acta Oncol. 2010;49:1109–15.
Henry AM, Stratford J, McCarthy C, et al. X-ray volume imaging in bladder radiotherapy verification. Int J Radiat Oncol Biol Phys. 2006;64:1174–8.
Pos F, Horenblas S, Dom P, et al. Organ preservation in invasive bladder cancer: brachytherapy, an alternative to cystectomy and combined modality treatment? Int J Radiat Oncol Biol Phys. 2005;61:678–86.
Hata M, Miyanaga N, Tokuuye K, et al. Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy. Int J Radiat Oncol Biol Phys. 2006;64:1371–9.
Foroudi F, Wilson L, Bressel M, et al. A dosimetric comparison of 3D conformal vs intensity modulated vs volumetric arc radiation therapy for muscle invasive bladder cancer. Radiat Oncol. 2012;7:111.
Hautmann RE, de Petriconi RC, Pfeiffer C, et al. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol. 2012;61:1039–47.
Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666–75.
Coppin CM, Gospodarowicz MK, James K, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1996;14:2901–7.
Nichols Jr RC, Sweetser MG, Mahmood SK, et al. Radiation therapy and concomitant paclitaxel/carboplatin chemotherapy for muscle invasive transitional cell carcinoma of the bladder: a well-tolerated combination. Int J Cancer. 2000;90:281–6.
Dunst J, Weigel C, Heynemann H, et al. Preliminary results of simultaneous radiochemotherapy with paclitaxel for urinary bladder cancer. Strahlenther Onkol. 1999;175 Suppl 3:7–10.
Colombo R, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol. 2003;21:4270–6.
van der Zee J, Gonzalez Gonzalez D, van Rhoon GC, et al. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet. 2000;355:1119–25.
Hoskin PJ, Rojas AM, Bentzen SM, et al. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol. 2010;28:4912–8.
Cohen-Jonathan E, Muschel RJ, Gillies McKenna W, et al. Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. Radiat Res. 2000;154:125–32.
Bellmunt J, Hussain M, Dinney CP. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol. 2003;46(Suppl):85–104.
Gospodarowicz MK, Hawkins NV, Rawlings GA, et al. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. J Urol. 1989;142:1448–53. discussion 1453–4.
Coen JJ, Paly JJ, Niemierko A, et al. Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2013;86:311–6.
Agerbaek M, Alsner J, Marcussen N, et al. Retinoblastoma protein expression is an independent predictor of both radiation response and survival in muscle-invasive bladder cancer. Br J Cancer. 2003;89:298–304.
Chakravarti A, Winter K, Wu CL, et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2005;62:309–17.
Chyle V, Pollack A, Czerniak B, et al. Apoptosis and downstaging after preoperative radiotherapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 1996;35:281–7.
Cooke PW, James ND, Ganesan R, et al. Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy. BJU Int. 2000;85: 829–35.
Garcia del Muro X, Condom E, Vigues F, et al. p53 and p21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer. 2004;100:1859–67.
Harada S, Sato R, Nakamura R, et al. The correlation between spontaneous and radiation-induced apoptosis in T3B bladder cancer (histological grade G3), and the precedence between the two kinds of apoptosis for predicting clinical prognosis. Int J Radiat Oncol Biol Phys. 2000;48:1059–67.
Hussain SA, Ganesan R, Hiller L, et al. BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder. Oncol Rep. 2003;10:571–6.
Jahnson S, Risberg B, Karlsson MG, et al. p53 and Rb immunostaining in locally advanced bladder cancer: relation to prognostic variables and predictive value for the local response to radical radiotherapy. Eur Urol. 1995;28:135–42.
Lara PC, Perez S, Rey A, et al. Apoptosis in carcinoma of the bladder: relation with radiation treatment results. Int J Radiat Oncol Biol Phys. 1999;43:1015–9.
Lara PC, Rey A, Santana C, et al. The role of Ki67 proliferation assessment in predicting local control in bladder cancer patients treated by radical radiation therapy. Radiother Oncol. 1998;49:163–7.
Moonen L, Ong F, Gallee M, et al. Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys. 2001;49:1305–10.
Ogura K, Habuchi T, Yamada H, et al. Immunohistochemical analysis of p53 and proliferating cell nuclear antigen (PCNA) in bladder cancer: positive immunostaining and radiosensitivity. Int J Urol. 1995;2:302–8.
Ong F, Moonen LM, Gallee MP, et al. Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53. Radiother Oncol. 2001;61:169–75.
Osen I, Fossa SD, Majak B, et al. Prognostic factors in muscle-invasive bladder cancer treated with radiotherapy: an immunohistochemical study. Br J Urol. 1998;81:862–9.
Pollack A, Czerniak B, Zagars GK, et al. Retinoblastoma protein expression and radiation response in muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 1997;39:687–95.
Pollack A, Wu CS, Czerniak B, et al. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin Cancer Res. 1997;3:1823–9.
Qureshi KN, Griffiths TR, Robinson MC, et al. Combined p21WAF1/CIP1 and p53 overexpression predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy. Int J Radiat Oncol Biol Phys. 2001;51:1234–40.
Rodel C, Grabenbauer GG, Rodel F, et al. Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. Int J Radiat Oncol Biol Phys. 2000;46:1213–21.
Rotterud R, Berner A, Holm R, et al. p53, p21 and mdm2 expression vs the response to radiotherapy in transitional cell carcinoma of the bladder. BJU Int. 2001;88:202–8.
Weiss C, Rodel F, Wolf I, et al. Combined-modality treatment and organ preservation in bladder cancer. Do molecular markers predict outcome? Strahlenther Onkol. 2005;181:213–22.
Wu CS, Pollack A, Czerniak B, et al. Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy. Urology. 1996;47:305–10.
Hoskin PJ, Sibtain A, Daley FM, et al. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer. 2003;89:1290–7.
Sak SC, Harnden P, Johnston CF, et al. APE1 and XRCC1 protein expression levels predict cancer-specific survival following radical radiotherapy in bladder cancer. Clin Cancer Res. 2005;11:6205–11.
Matsumoto H, Wada T, Fukunaga K, et al. Bax to Bcl-2 ratio and Ki-67 index are useful predictors of neoadjuvant chemoradiation therapy in bladder cancer. Jpn J Clin Oncol. 2004;34:124–30.
Koga F, Yoshida S, Tatokoro M, et al. ErbB2 and NFkappaB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancer. PLoS One. 2011;6:e27616.
Choudhury A, Nelson LD, Teo MT, et al. MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res. 2010;70:7017–26.
Rotterud R, Pettersen EO, Berner A, et al. Cell cycle inhibitors and outcome after radiotherapy in bladder cancer patients. Acta Oncol. 2002;41:463–70.
Laurberg JR, Brems-Eskildsen AS, Nordentoft I, et al. Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer. BJU Int. 2012;110:E1228–36.
Weiss C, Rodel F, Ott O, et al. Pretreatment proliferation and local control in bladder cancer after radiotherapy with or without concurrent chemotherapy. Strahlenther Onkol. 2007;183:552–6.
Hug EB, Donnelly SM, Shipley WU, et al. Deoxyribonucleic acid flow cytometry in invasive bladder carcinoma: a possible predictor for successful bladder preservation following transurethral surgery and chemotherapy-radiotherapy. J Urol. 1992;148:47–51.
Jenkins BJ, Martin JE, Baithun SI, et al. Prediction of response to radiotherapy in invasive bladder cancer. Br J Urol. 1990;65:345–8.
Wijkstrom H, Tribukait B. Deoxyribonucleic acid flow cytometry in predicting response to radical radiotherapy of bladder cancer. J Urol. 1990;144:646–50.
Sherwood BT, Colquhoun AJ, Richardson D, et al. Carbonic anhydrase IX expression and outcome after radiotherapy for muscle-invasive bladder cancer. Clin Oncol (R Coll Radiol). 2007;19:777–83.
Weiss C, von Romer F, Capalbo G, et al. Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy. Int J Radiat Oncol Biol Phys. 2009;74:1455–60.
Lautenschlaeger T, George A, Klimowicz AC, et al. Bladder preservation therapy for muscle-invading bladder cancers on radiation therapy oncology group trials 8802, 8903, 9506, and 9706: vascular endothelial growth factor B overexpression predicts for increased distant metastasis and shorter survival. Oncologist. 2013;18:685–6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Weiss, C., Rödel, C. (2015). Chemoradiotherapy. In: Konety, B., Chang, S. (eds) Management of Bladder Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1881-2_28
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1881-2_28
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-1880-5
Online ISBN: 978-1-4939-1881-2
eBook Packages: MedicineMedicine (R0)